Mariner
PRQR icon

Mariner’s ProQR Therapeutics PRQR Stock Holding History

Mariner’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.5K Hold
20,169
– – ﹤0.01% 3437
2026
Q1 		$32.7K Buy
20,169
+950
+5% +$1.56K ﹤0.01% 3462
2025
Q4 		$38.8K Hold
19,219
– – ﹤0.01% 3439
2025
Q3 		$40.9K Hold
19,219
– – ﹤0.01% 3469
2025
Q2 		$39.2K Buy
19,219
+885
+5% +$1.44K ﹤0.01% 3370
2025
Q1 		$24.4K Hold
18,334
– – ﹤0.01% 3363
2024
Q4 		$48.6K Hold
18,334
– – ﹤0.01% 3291
2024
Q3 		$33.5K Hold
18,334
– – ﹤0.01% 3222
2024
Q2 		$30.4K Hold
18,334
– – ﹤0.01% 3087
2024
Q1 		$42K Hold
18,334
– – ﹤0.01% 3046
2023
Q4 		$36.3K Hold
18,334
– – ﹤0.01% 2965
2023
Q3 		$23.8K Hold
18,334
– – ﹤0.01% 2834
2023
Q2 		$29.7K Hold
18,334
– – ﹤0.01% 2760
2023
Q1 		$39K Hold
18,334
– – ﹤0.01% 2671
2022
Q4 		$68K Buy
+18,334
New +$24K ﹤0.01% 2582

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Mariner's PRQR Position: Q2 2026 in Review

Mariner held its ProQR Therapeutics (PRQR) position steady in Q2 2026 at 20,169 shares worth $37.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3437.

Mariner first reported a position in PRQR in Q4 2022 and has held it in 15 quarters since. The position peaked at $68K in Q4 2022. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Mariner held 20,169 shares of ProQR Therapeutics worth $37.5K as of Q2 2026.
  • Mariner left its ProQR Therapeutics share count unchanged in Q2 2026.
  • ProQR Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #3437 holding.
  • Mariner first reported a position in ProQR Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Mariner's ProQR Therapeutics position peaked at $68K in Q4 2022.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.